Using engineered gut bacteria to fight genetic disease

synbio

A Boston-based synthetic biology company is taking a novel approach to treating the rare genetic metabolic disorder Phenylketonuria. Synlogic uses genetic engineering; but instead of trying to alter patients’ genes, the company is focused on modifying gut bacteria.

 Phenylketonuria (PKU) is a genetic metabolic disorder, where the patients cannot properly metabolize the amino acid phenylalanine (Phe). It is an inherited condition, caused by low levels of the enzyme phenylalanine hydroxylase (PAH) (or non-functional recycling pathway of the co-factor THB, required by phenylalanine hydroxylase).

PKU is a serious condition. If untreated, PKU symptoms include mental and behaviour disorders, seizures, light skin, and musty smell. Newborn screening can reveal very quickly the imbalance in the amino acid metabolism, and patients can lead a normal life if they have extremely low-phenylalanine diet. Maintain a lifelong prescription diet is challenging, associated with high costs and social limitations.

There is a very limited amount of non-dietary treatment options and no cure is available. One approved therapy is the continuous injection of PEGylated phenylalanine ammonia lyase (PAL), an enzyme that degrades phenylalanine; however this treatment comes at a high cost and with severe anaphylaxis risk. KUVAN is a PAH activator—effective in patients with poor availability of co-factor THB—is not applicable to many patients and cannot replace low-phenylalanine diet. Gene therapy could solve the problem once and for all, essentially fixing the patient’s non-functional enzyme at the DNA level. However, there is no such treatment approved yet.

Synlogic decided to take a different approach. Instead of attempting to modify the genome of the patient, the company decided to focus on the microbiome. Their idea is to modify Escherichia coli Nissle, a bacterium naturally occurring in the human microbiome, to break down phenylalanine before it damages the host.

The results of this effort were recently reported in Nature Biotechnology, while a clinical trial is underway. The researchers engineered E. coli with two Phe-catabolising enzymes: one is PAL, a cytosolic enzyme; the other is the L-amino acid deaminase (LAAD), which converts Phe to phenylpyruvate. Both enzymes have different limitations. As PAL is located inside the cell, it requires a phenylalanine importer to bring Phe in and catabolise it. LAAD localises in the external membrane, but requires oxygen for its function—oxygen that is scarcely found in the human intestines. Both pathways work, as they reduce Phe concentration in the assays; however, the bacteria expressing them were growing really slowly.

Related article:  Is depression affected by bacteria in the gut?

Given the first encouraging results, the Synlogic researchers proceeded to construct the final strain. The researchers wanted a strain that would activate the Phe-degrading pathways only when in the gut, in a precise manner. They also wanted the LAAD enzyme to be expressed in microaerobic environment (where it has activity). Moreover, the strains would need to harbour no antibiotic resistance cassettes (to be used in humans) and have the transgenes incorporated in the genome (for stability). The final E. coli strain SYNB1618 satisfied all these requirements, with the addition of a biocontainment switch to prevent it from release into the environment.

Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.

The final strain’s efficiency as a phenylalanine regulator was experimentally tested in mice with PKU and in healthy monkeys. In both cases, the researchers detected degradation products caused by the heterologous enzymes secreted in the urine, without any side effect. Also, they report that unhealthy mice injected with the probiotic strain reduced their phenylalanile blood levels by 38%. As clinical trials proceed, Synlogic just announced positive initial results for the ongoing Phase 1/2a clinical trial.

This treatment approach is pioneering. Things looks promising so far, so I am looking forward to the clinical results. SYNB1618 could act as a regulator of Phe, especially in adult PKU patients that have trouble maintaining a prescription diet. Synlogic has a rich portfolio of probiotic strains as treatment to metabolic disorders (trademarked as Synthetic Biotics™), in various stages of trial as therapeutics. Their metabolic disease portfolio includes other conditions, such as hyperammonemia and maple syrup urine disease. Exploiting the microbiome for therapeutic applications is a fascinating and promising direction, and I expect to see more in the future.

Dr. Konstantinos (Kostas) Vavitsas is a postdoctoral fellow at the University of Queensland, on expanding the synthetic biology potential of cyanobacteria. He is a member of the executive board of Synthetic Biology Australasia, and community editor for PLOS synbio. Follow him on Twitter @konvavitsas

A version of this story originally ran at PLOS as Synthetic probiotics for genetic disease treatment and has been republished here with permission.

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
can you boost your immune system to prevent coronavirus spread x

Video: How to boost your immune system to guard against COVID and other illnesses

Scientists have recently developed ways to measure your immune age. Fortunately, it turns out your immune age can go down ...
mag insects image superjumbo v

Disaster interrupted: Which farming system better preserves insect populations: Organic or conventional?

A three-year run of fragmentary Armageddon-like studies had primed the journalism pumps and settled the media framing about the future ...
dead bee desolate city

Are we facing an ‘Insect Apocalypse’ caused by ‘intensive, industrial’ farming and agricultural chemicals? The media say yes; Science says ‘no’

The media call it the “Insect Apocalypse”. In the past three years, the phrase has become an accepted truth of ...
globalmethanebudget globalcarbonproject cropped x

Infographic: Cows cause climate change? Agriculture scientist says ‘belching bovines’ get too much blame

A recent interview by Caroline Stocks, a UK journalist who writes about food, agriculture and the environment, of air quality ...
organic hillside sweet corn x

Organic v conventional using GMOs: Which is the more sustainable farming?

Many consumers spend more for organic food to avoid genetically modified products in part because they believe that “industrial agriculture” ...
benjamin franklin x

Are most GMO safety studies funded by industry?

The assertion that biotech companies do the research and the government just signs off on it is false ...
gmo corn field x

Do GMO Bt (insect-resistant) crops pose a threat to human health or the environment?

Bt is a bacterium found organically in the soil. It is extremely effective in repelling or killing target insects but ...
favicon

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies for tighter GMO legislation and famously puts out annual "dirty dozen" list of fruits and ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be the prime mover behind the ongoing campaign against agricultural biotechnology at Consumer Reports. He is an ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend